Literature DB >> 16555976

Cancer immunoprevention.

Pier-Luigi Lollini1, Carla De Giovanni, Tania Pannellini, Federica Cavallo, Guido Forni, Patrizia Nanni.   

Abstract

Immunoprevention is a fresh approach to cancer prevention based on the stimulation of the immune system before tumor onset. Immunoprevention was effective in various models of carcinogen-induced or autochthonous tumor progression. Vaccines made of cells or DNA plasmids combined with appropriate adjuvants completely blocked mammary carcinogenesis in HER-2/neu transgenic mice. At variance with cancer immunotherapy, the mediators of immunoprevention are antibodies and T-cell-derived cytokines, rather than cytotoxic T-cells. Immunopreventive approaches and chemoprevention with tamoxifen or cyclooxygenase-2 inhibitors can be combined advantageously. The success obtained in preclinical studies suggests that cancer immunoprevention should progress to clinical testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16555976     DOI: 10.1517/14796694.1.1.57

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  13 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

2.  Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Authors:  Gaetano Donofrio; Giulia Tebaldi; Stefania Lanzardo; Roberto Ruiu; Elisabetta Bolli; Andrea Ballatore; Valeria Rolih; Francesca Macchi; Laura Conti; Federica Cavallo
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

3.  Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs.

Authors:  S D Reed; A Fulmer; J Buckholz; B Zhang; J Cutrera; K Shiomitsu; S Li
Journal:  Cancer Gene Ther       Date:  2010-02-12       Impact factor: 5.987

Review 4.  Immune responses to malignancies.

Authors:  Theresa L Whiteside
Journal:  J Allergy Clin Immunol       Date:  2010-01-12       Impact factor: 10.793

5.  Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.

Authors:  Maha Z Ladjemi; Thierry Chardes; Stephanie Corgnac; Veronique Garambois; Sebastien Morisseau; Bruno Robert; Caroline Bascoul-Mollevi; Imade Ait Arsa; William Jacot; Jean-Pierre Pouget; Andre Pelegrin; Isabelle Navarro-Teulon
Journal:  Breast Cancer Res       Date:  2011-02-04       Impact factor: 6.466

6.  Modelling vaccination schedules for a cancer immunoprevention vaccine.

Authors:  Santo Motta; Filippo Castiglione; Pierluigi Lollini; Francesco Pappalardo
Journal:  Immunome Res       Date:  2005-10-07

7.  Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator.

Authors:  Pier-Luigi Lollini; Santo Motta; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2006-07-20       Impact factor: 3.169

8.  A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY.

Authors:  Francesco Pappalardo; Marie-Paule Lefranc; Pier-Luigi Lollini; Santo Motta
Journal:  Immunome Res       Date:  2010-02-18

Review 9.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

10.  Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.

Authors:  Elena Quaglino; Federica Riccardo; Marco Macagno; Silvio Bandini; Rodica Cojoca; Elisabetta Ercole; Augusto Amici; Federica Cavallo
Journal:  Cancers (Basel)       Date:  2011-08-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.